X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (26251) 26251
Publication (1467) 1467
Book Review (343) 343
Book Chapter (103) 103
Magazine Article (85) 85
Book / eBook (82) 82
Conference Proceeding (53) 53
Web Resource (21) 21
Dissertation (10) 10
Paper (5) 5
Journal / eJournal (4) 4
Reference (4) 4
Data Set (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (23548) 23548
fibrinolytic agents - therapeutic use (16634) 16634
male (11618) 11618
female (10717) 10717
index medicus (8714) 8714
middle aged (8188) 8188
aged (7789) 7789
fibrinolytic agents - administration & dosage (6343) 6343
treatment outcome (5995) 5995
thrombolytic therapy (4612) 4612
adult (4583) 4583
peripheral vascular disease (4175) 4175
fibrinolytic agents - adverse effects (4164) 4164
tissue plasminogen activator - therapeutic use (3885) 3885
time factors (3565) 3565
risk factors (3543) 3543
animals (3511) 3511
cardiac & cardiovascular systems (3465) 3465
myocardial infarction - drug therapy (3337) 3337
stroke (3317) 3317
thrombolysis (3199) 3199
stroke - drug therapy (3106) 3106
aged, 80 and over (3027) 3027
clinical neurology (2878) 2878
anticoagulants - therapeutic use (2807) 2807
thrombolytic therapy - methods (2517) 2517
fibrinolytic agents - pharmacology (2511) 2511
hematology (2313) 2313
therapy (2305) 2305
retrospective studies (2275) 2275
tissue plasminogen activator - administration & dosage (2256) 2256
thrombosis (2081) 2081
thrombosis - drug therapy (2002) 2002
medicine, general & internal (1967) 1967
surgery (1875) 1875
platelet aggregation inhibitors - therapeutic use (1871) 1871
heparin - therapeutic use (1867) 1867
acute disease (1765) 1765
mortality (1708) 1708
prospective studies (1679) 1679
brain ischemia - drug therapy (1615) 1615
care and treatment (1598) 1598
drug therapy, combination (1535) 1535
follow-up studies (1520) 1520
management (1499) 1499
aspirin - therapeutic use (1495) 1495
tissue plasminogen activator (1487) 1487
myocardial infarction - therapy (1456) 1456
acute ischemic-stroke (1447) 1447
streptokinase - therapeutic use (1425) 1425
anticoagulants (1397) 1397
tissue-plasminogen activator (1369) 1369
fibrinolysis (1365) 1365
prognosis (1345) 1345
acute myocardial-infarction (1324) 1324
trial (1297) 1297
pharmacology & pharmacy (1292) 1292
risk (1283) 1283
aspirin (1273) 1273
electrocardiography (1226) 1226
abridged index medicus (1201) 1201
prevention (1200) 1200
thrombolytic therapy - adverse effects (1194) 1194
pulmonary embolism - drug therapy (1178) 1178
drug therapy (1177) 1177
hemorrhage - chemically induced (1173) 1173
neurosciences (1170) 1170
heparin (1167) 1167
clinical trials as topic (1159) 1159
randomized controlled trials as topic (1154) 1154
risk assessment (1153) 1153
ischemia (1138) 1138
recombinant proteins - therapeutic use (1107) 1107
tissue plasminogen activator - adverse effects (1051) 1051
recurrence (1045) 1045
rats (1044) 1044
myocardial infarction - mortality (1040) 1040
stroke - etiology (1019) 1019
alteplase (1013) 1013
medicine & public health (994) 994
analysis (983) 983
tomography, x-ray computed (975) 975
infusions, intravenous (974) 974
fibrinolytic therapy (956) 956
neurology (939) 939
dose-response relationship, drug (930) 930
adolescent (929) 929
fibrinolytic agents (924) 924
myocardial infarction (911) 911
angioplasty, balloon, coronary (908) 908
anticoagulants - administration & dosage (905) 905
thrombosis - prevention & control (886) 886
cardiovascular (884) 884
stroke - therapy (870) 870
molecular-weight heparin (869) 869
thromboembolism (867) 867
combined modality therapy (863) 863
stroke - prevention & control (853) 853
thrombosis - etiology (849) 849
anticoagulants - adverse effects (841) 841
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (58) 58
Online Resources - Online (22) 22
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
UofT at Mississauga - Stacks (2) 2
Gerstein Science - Periodical Stacks (1) 1
Gerstein Science - Theses (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Scarborough Hospital - Birchmount (1) 1
Scarborough Hospital - General (1) 1
Scarborough Hospital - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
University Archives - Archives (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (22409) 22409
German (990) 990
French (730) 730
Russian (465) 465
Spanish (421) 421
Italian (336) 336
Japanese (259) 259
Polish (167) 167
Chinese (162) 162
Danish (81) 81
Norwegian (67) 67
Portuguese (65) 65
Hungarian (59) 59
Dutch (53) 53
Swedish (48) 48
Finnish (39) 39
Czech (36) 36
Turkish (31) 31
Romanian (24) 24
Hebrew (19) 19
Bulgarian (18) 18
Ukrainian (18) 18
Serbian (12) 12
Croatian (11) 11
Korean (8) 8
Lithuanian (6) 6
Slovak (6) 6
Icelandic (3) 3
Afrikaans (1) 1
Catalan (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e326S - e350S
Background: This guideline addresses the management of patients who are receiving anticoagulant or antiplatelet therapy and require an elective surgery or... 
VITAMIN-K-ANTAGONISTS | PERCUTANEOUS CORONARY INTERVENTION | PROSTHETIC HEART-VALVES | LOW-DOSE ASPIRIN | RESPIRATORY SYSTEM | MOLECULAR-WEIGHT HEPARIN | ORAL ANTICOAGULANT-THERAPY | TRANEXAMIC ACID MOUTHWASH | NONVALVULAR ATRIAL-FIBRILLATION | INTERNATIONAL NORMALIZED RATIO | DRUG-ELUTING STENTS | CRITICAL CARE MEDICINE | Perioperative Care | United States | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Aspirin - pharmacokinetics | Angioplasty, Balloon, Coronary | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - pharmacokinetics | Postoperative Complications - drug therapy | Thrombosis - blood | Thrombosis - prevention & control | Stents | Platelet Aggregation Inhibitors - adverse effects | Drug Administration Schedule | Atrial Fibrillation - drug therapy | Heart Valve Prosthesis | Risk Factors | Atrial Fibrillation - complications | Evidence-Based Medicine | Atrial Fibrillation - blood | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Elective Surgical Procedures | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e152S - e184S
Background: High-quality anticoagulation management is required to keep these narrow therapeutic index medications as effective and safe as possible. This... 
COMPUTERIZED DECISION-SUPPORT | INTENSITY WARFARIN THERAPY | DEFINITE ANTIPHOSPHOLIPID SYNDROME | RESPIRATORY SYSTEM | PROTHROMBIN COMPLEX CONCENTRATE | MOLECULAR-WEIGHT HEPARIN | DEEP-VEIN THROMBOSIS | INTERNATIONAL NORMALIZED RATIO | NONVALVULAR ATRIAL-FIBRILLATION | ACUTE VENOUS THROMBOEMBOLISM | ORAL VITAMIN-K | CRITICAL CARE MEDICINE | United States | Humans | Decision Support Systems, Clinical | Heparin - therapeutic use | Hemorrhage - prevention & control | Long-Term Care | Heparin - adverse effects | Heparin - pharmacokinetics | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Drug Interactions | Societies, Medical | Fibrinolytic Agents - pharmacokinetics | Drug-Related Side Effects and Adverse Reactions | Fibrinolytic Agents - therapeutic use | Thrombosis - blood | Thrombosis - prevention & control | Patient Education as Topic | Polysaccharides - therapeutic use | Drug Administration Schedule | Administration, Oral | Hemorrhage - therapy | Polysaccharides - adverse effects | Evidence-Based Medicine | Randomized Controlled Trials as Topic | International Normalized Ratio | Thrombosis - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Self Care | Polysaccharides - pharmacokinetics | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e669S - e690S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e1S - e23S
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e419S - e496S
Background: This article addresses the treatment of VTE disease. Methods: We generated strong (Grade 1) and weak (Grade 2) recommendations based on... 
RIGHT-VENTRICULAR DYSFUNCTION | RECURRENT VENOUS THROMBOEMBOLISM | TISSUE-PLASMINOGEN-ACTIVATOR | RESPIRATORY SYSTEM | ACUTE PULMONARY-EMBOLISM | MOLECULAR-WEIGHT HEPARIN | VENA-CAVA FILTER | ORAL ANTICOAGULANT-THERAPY | INTRAVENOUS UNFRACTIONATED HEPARIN | LONG-TERM TREATMENT | DEEP-VEIN-THROMBOSIS | CRITICAL CARE MEDICINE | Venous Thrombosis - diagnosis | Pulmonary Embolism - prevention & control | United States | Humans | Venous Thrombosis - blood | Heparin, Low-Molecular-Weight - adverse effects | Hemorrhage - prevention & control | Long-Term Care | Heparin, Low-Molecular-Weight - therapeutic use | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Fibrinolytic Agents - therapeutic use | Venous Thrombosis - prevention & control | Polysaccharides - therapeutic use | Drug Administration Schedule | Venous Thrombosis - drug therapy | Administration, Oral | Risk Factors | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Pulmonary Embolism - blood | International Normalized Ratio | Diagnostic Imaging | Pulmonary Embolism - diagnosis | Pulmonary Embolism - drug therapy | Hemorrhage - chemically induced | Infusions, Intravenous | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e531S - e575S
Background: The risk of stroke varies considerably across different groups of patients with atrial fibrillation (AF). Antithrombotic prophylaxis for stroke is... 
DIRECT-CURRENT CARDIOVERSION | STROKE PREVENTION | RESPIRATORY SYSTEM | CLOPIDOGREL PLUS ASPIRIN | ORAL ANTICOAGULANT-THERAPY | RISK STRATIFICATION SCHEMES | MAJOR VASCULAR EVENTS | PULMONARY-VEIN ABLATION | ACUTE CORONARY SYNDROME | ECHOCARDIOGRAPHY-GUIDED CARDIOVERSION | ANTIARRHYTHMIC-DRUG THERAPY | CRITICAL CARE MEDICINE | Ticlopidine - therapeutic use | Humans | Electric Countershock | Hemorrhage - prevention & control | Dabigatran | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ticlopidine - adverse effects | Aspirin - therapeutic use | Benzimidazoles - adverse effects | Drug Therapy, Combination | beta-Alanine - analogs & derivatives | Benzimidazoles - therapeutic use | Stroke - prevention & control | beta-Alanine - adverse effects | Administration, Oral | Atrial Fibrillation - drug therapy | Risk Factors | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Ticlopidine - analogs & derivatives | Atrial Fibrillation - blood | International Normalized Ratio | Stroke - blood | Atrial Flutter - complications | Atrial Flutter - drug therapy | Hemorrhage - chemically induced | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e737S - e801S
Background: Neonates and children differ from adults in physiology, pharmacologic responses to drugs, epidemiology, and long-term consequences of thrombosis.... 
INFERIOR VENA-CAVA | TISSUE-PLASMINOGEN-ACTIVATOR | ARTERIAL ISCHEMIC-STROKE | RESPIRATORY SYSTEM | CEREBRAL SINOVENOUS THROMBOSIS | ACUTE LYMPHOBLASTIC-LEUKEMIA | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | HEPARIN-INDUCED THROMBOCYTOPENIA | SICKLE-CELL-DISEASE | HOMOZYGOUS PROTEIN-C | CRITICAL CARE MEDICINE | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Humans | Upper Extremity Deep Vein Thrombosis - blood | Child, Preschool | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Upper Extremity Deep Vein Thrombosis - prevention & control | Hemorrhage - prevention & control | Secondary Prevention | Heparin - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Cardiac Catheterization | Vitamin K - antagonists & inhibitors | Societies, Medical | Platelet Aggregation Inhibitors - administration & dosage | Renal Veins | Thrombosis - blood | Thrombosis - prevention & control | Child | Infant, Newborn | Platelet Aggregation Inhibitors - adverse effects | Upper Extremity Deep Vein Thrombosis - drug therapy | Drug Administration Schedule | Risk Factors | Cooperative Behavior | Hemorrhage - blood | Anticoagulants - adverse effects | Evidence-Based Medicine | Interdisciplinary Communication | Thrombosis - etiology | Blood Coagulation Tests | Fibrinolytic Agents - administration & dosage | Thrombosis - drug therapy | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e576S - e600S
Background: Antithrombotic therapy in valvular disease is important to mitigate thromboembolism, but the hemorrhagic risk imposed must be considered. Methods:... 
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heart Valve Diseases - blood | Mitral Valve | Thrombosis - complications | Ductus Arteriosus, Patent - drug therapy | Humans | Postoperative Complications - blood | Postoperative Complications - prevention & control | Stroke - complications | Hemorrhage - prevention & control | Rheumatic Heart Disease - blood | Fibrinolytic Agents - adverse effects | Vitamin K - antagonists & inhibitors | Societies, Medical | Ductus Arteriosus, Patent - blood | Thromboembolism - prevention & control | Aspirin - adverse effects | Heart Valve Diseases - complications | Fibrinolytic Agents - therapeutic use | Rheumatic Heart Disease - drug therapy | Rheumatic Heart Disease - complications | Aspirin - therapeutic use | Thromboembolism - drug therapy | Postoperative Complications - drug therapy | Thrombosis - blood | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Catheterization | Heart Atria | Heart Valve Prosthesis | Risk Factors | Ductus Arteriosus, Patent - complications | Combined Modality Therapy | Evidence-Based Medicine | Stroke - blood | Thromboembolism - blood | Heart Valve Diseases - drug therapy | Thrombosis - drug therapy | Hemorrhage - chemically induced | Thrombolytic Therapy - adverse effects | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e601S - e636S
Objectives: This article provides recommendations on the use of antithrombotic therapy in patients with stroke or transient ischemic attack (TIA). Methods: We... 
HIGH-RISK PATIENTS | TISSUE-PLASMINOGEN ACTIVATOR | CEREBRAL VENOUS THROMBOSIS | PATENT FORAMEN OVALE | RESPIRATORY SYSTEM | LONG-TERM SURVIVAL | LOW-MOLECULAR-WEIGHT | DEEP-VEIN THROMBOSIS | ASPIRIN PLUS DIPYRIDAMOLE | NONVALVULAR ATRIAL-FIBRILLATION | EXTENDED-RELEASE DIPYRIDAMOLE | CRITICAL CARE MEDICINE | Recombinant Proteins - therapeutic use | United States | Humans | Heparin - therapeutic use | Tissue Plasminogen Activator - therapeutic use | Intracranial Thrombosis - prevention & control | Recombinant Proteins - adverse effects | Heparin - adverse effects | Tissue Plasminogen Activator - adverse effects | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Societies, Medical | Aspirin - adverse effects | Fibrinolytic Agents - therapeutic use | Ischemic Attack, Transient - etiology | Aspirin - therapeutic use | Intracranial Thrombosis - drug therapy | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Ischemic Attack, Transient - drug therapy | Intermittent Pneumatic Compression Devices | Intracranial Thrombosis - blood | Combined Modality Therapy | Stroke - drug therapy | Evidence-Based Medicine | Stroke - blood | Intracranial Thrombosis - etiology | Thrombolytic Therapy | Ischemic Attack, Transient - blood | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
1988, ISBN 9780808918912, xii, 306
Book
1990, ISBN 0702014745, Volume 3/no. 3., x, p. 483-836.
Book
Journal Article
The Lancet, ISSN 0140-6736, 2001, Volume 357, Issue 9272, pp. 1905 - 1914
Journal Article